Liu Peng, Wang Yi, Yang Ren-chi, Gu Jie, Cai Ying-lin, Han Zhong-chao
State Key Laboratory of Experimental Hematology, Institute of Hematology, Blood Diseases Hospital, CAMS, PUMC, Tianjin 300020, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Jun;25(3):312-5.
To construct recombinant adenoviruses expressing antiangiogenic fragment of human thrombospondin1 (TSP1f).
TSP1f cDNA was amplified by RT-PCR from normal human peripheral blood mononuclear cells and was subcloned into a shuttle vector pShuttle-CMV. After sequence confirmation, the resultant plasmid was linearized by the restriction endonuclease Pme I and cotransformed with the supercoiled adenoviral vector pAdEasy-1 into Escherichia coli strain BJ5183. Recombinants were selected by Kanamycin resistance and screened by restriction endonuclease digestion. Then, the recombinant adenoviral construct was cleaved with Pac I and transfected into the packaging cell line 293. The adenoviral vector ADV-TSP1f was propagated in 293 cells and purified by cesium chloride (CsCl) density centrifugation. PCR and Western blot analysis were performed to confirm TSP1f expression.
Of 43 Kanamycin-resistant colonies obtained from cotransformation, all of the 10 smallest ones were the correct recombinants. TSP-1f was expressed efficiently by ADV-TSP1f. The virus stock titer after CsCl banding was 1.0 x 10(11) pfu/mL.
Generating recombinant adenoviruses using AdEasy System results in highly efficient viral production and significantly decrease the time required to construct usable viruses. ADV-TSP1f can be further used in in vivo gene therapy studies.
构建表达人血小板反应蛋白1(TSP1)抗血管生成片段的重组腺病毒。
通过RT-PCR从正常人外周血单个核细胞中扩增TSP1f cDNA,并将其亚克隆到穿梭载体pShuttle-CMV中。序列确认后,用限制性内切酶Pme I将所得质粒线性化,并与超螺旋腺病毒载体pAdEasy-1共转化到大肠杆菌菌株BJ5183中。通过卡那霉素抗性筛选重组体,并通过限制性内切酶消化进行筛选。然后,用Pac I切割重组腺病毒构建体并转染到包装细胞系293中。腺病毒载体ADV-TSP1f在293细胞中繁殖,并通过氯化铯(CsCl)密度离心纯化。进行PCR和蛋白质印迹分析以确认TSP1f的表达。
从共转化获得的43个卡那霉素抗性菌落中,10个最小的菌落均为正确的重组体。ADV-TSP1f有效表达TSP-1f。CsCl分级后的病毒原液滴度为1.0×10(11) pfu/mL。
使用AdEasy系统产生重组腺病毒可实现高效病毒生产,并显著缩短构建可用病毒所需的时间。ADV-TSP1f可进一步用于体内基因治疗研究。